As the pharmaceutical and biotech industries face pending healthcare and biologics legislation, the future of the industry remains in flux. Many companies have generics coming off patent necessitating discussion on new investments, pipeline issues and increased research & development.

On June 22nd, Argyle Executive Forum will host its Leadership in Pharmaceuticals and Biotechnology event, taking place in Manhattan. The event brings together approximately 100 - 115 CEO’s and complementary areas of executive leadership, from large and midsized pharmaceutical and biotech companies, founders/senior managing partners of investment firms that focus on pharmaceuticals and biotechnology and select advisors.

Please note that the limited seating for members of the advisory community is offered first to those that are supporting the event as sponsors. Participation by partnership organizations (advisory firms, vendors, etc) is limited to clients of Argyle Executive Forum. Argyle meetings are by invitation only. If you did not receive an invitation but would like to inquire about attendance, please click here.

*Press policies for member meetings are set at the individual session level. Some sessions may be on the record, while others are off. Please consult the meeting agenda, which will indicate which sessions are off the record. To inquire about media presence, please click here.

Perspectives By:

Mark Altmeyer
President and Chief Executive Officer
Otsuka America Pharmaceutical, Inc.

Mike Chace-Ortiz
Senior Director of Product Strategy
Thomson Reuters

David H. Donabedian, PhD, MBA
Vice President, Strategic Alliances
US CEEDD, GSK

Dimitri Drone
Transaction Services Pharmaceutical and Life Sciences Leader
PricewaterhouseCoopers

Stephen Evans-Freke
Co-Founder and Managing General Partner 
Celtic Therapeutics

David Fox
Partner
Hogan Lovells US LLP

Chris Garabedian
Vice President, Corporate Strategy
Celgene Corporation

Adam Golden
Partner and Co-Chair, Life Sciences Group 
Kaye Scholer LLP

Wendy Goldstein
Member of the Firm
Epstein Becker & Green PC

Elaine V. Jones, Ph.D.
Executive Director, Venture Capital- Worldwide Business Development
Pfizer Inc.

Jessica Kirk
Vice President - Life Sciences
Gerson Lehrman Group

Julius Knowles
Head, Platforms, Strategic Alliances
Novartis Institutes for BioMedical Research

Reid J. Leonard, Ph.D. 
Executive Director, Licensing & External Research 
Merck Research Laboratories

Rod MacKenzie 
Senior Vice President, Head of PharmaTherapeutics R&D
Pfizer Inc

Michael Mentesana
US Pharmaceutical and Life Sciences R&D Advisory Services Leader 
PricewaterhouseCoopers

Veronica Mullally
Partner
Hogan Lovells

Garry Neil, MD
Corporate Vice President, Corporate Office of Science & Technology
Johnson & Johnson

Richard C. Pasternak
VP, Head Global Scientific Affairs and Scientific Leadership 
Merck

Mark Powell
Senior Vice President, Pharmaceutical Development
Bristol-Myers Squibb

Paunie Samreth
Reporter
mergermarket

Dr. Robert J. Spiegel, M.D. 
Former Chief Medical Officer and Senior Vice President, Schering-Plough Corporation
and
Founder, Spiegel Consulting LLC

Elizabeth Stoner, M.D., M.S.
Managing Director
MPM Capital

Robert L. Ullmann
Chair, Government Investigations and White Collar Defense
Nutter McClennen & Fish LLP

Hans Vemer
Former Senior Vice President- Women’s Health
Schering-Plough

Mike Wise
Vice President and Partner
A.T. Kearney